Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$2.05
+0.5%
$1.96
$1.41
$2.79
$93.18M1.4667,296 shs44,516 shs
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
$1.88
+0.5%
$1.72
$1.40
$7.88
$83.45M1.56370,560 shs328,689 shs
eXoZymes Inc. stock logo
EXOZ
eXoZymes
$9.25
$12.16
$8.50
$23.99
$77.40MN/A11,602 shs1,872 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.49
+2.3%
$3.36
$2.57
$6.88
$21.56M0.629,120 shs2,140 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entera Bio Ltd. stock logo
ENTX
Entera Bio
0.00%+18.50%+3.02%+14.53%+8.47%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
0.00%+9.94%+11.24%+5.03%-67.02%
eXoZymes Inc. stock logo
EXOZ
eXoZymes
0.00%-5.71%-25.10%-14.67%+924,999,900.00%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%0.00%+1.48%+29.74%-40.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2.1787 of 5 stars
3.55.00.00.00.60.80.0
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
1.0086 of 5 stars
1.02.00.00.02.32.51.3
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entera Bio Ltd. stock logo
ENTX
Entera Bio
3.00
Buy$10.00387.80% Upside
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
2.00
Hold$2.006.38% Upside
eXoZymes Inc. stock logo
EXOZ
eXoZymes
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entera Bio Ltd. stock logo
ENTX
Entera Bio
$180K517.63N/AN/A$0.23 per share8.91
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/A$2.81 per shareN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
$70K1,106.04N/AN/A$1.25 per share7.40
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.19N/AN/A$13.32 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$28.54M-$0.63N/AN/AN/AN/A-23.48%-22.86%8/4/2025 (Estimated)
eXoZymes Inc. stock logo
EXOZ
eXoZymes
-$5.86MN/A0.00N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/25/2025 (Estimated)

Latest NAII, EPIX, EXOZ, and ENTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.11N/AN/AN/AN/AN/A
8/4/2025Q3 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.2430N/AN/AN/AN/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/A-$0.22N/A-$0.22N/AN/A
5/9/2025Q1 2025
Entera Bio Ltd. stock logo
ENTX
Entera Bio
-$0.07-$0.06+$0.01-$0.06N/A$0.04 million
5/8/2025Q2 2025
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
-$0.19-$0.14+$0.05-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/AN/AN/AN/AN/A
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/AN/AN/AN/AN/A
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entera Bio Ltd. stock logo
ENTX
Entera Bio
N/A
13.07
13.07
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
N/A
67.15
67.15
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/A
6.52
6.52
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35

Institutional Ownership

CompanyInstitutional Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
14.11%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
75.12%
eXoZymes Inc. stock logo
EXOZ
eXoZymes
N/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%

Insider Ownership

CompanyInsider Ownership
Entera Bio Ltd. stock logo
ENTX
Entera Bio
10.38%
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
15.50%
eXoZymes Inc. stock logo
EXOZ
eXoZymes
72.41%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entera Bio Ltd. stock logo
ENTX
Entera Bio
2045.45 million40.73 millionOptionable
ESSA Pharma Inc. stock logo
EPIX
ESSA Pharma
5044.39 million37.51 millionOptionable
eXoZymes Inc. stock logo
EXOZ
eXoZymes
298.37 million2.31 millionN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable

Recent News About These Companies

Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results
CarnoSyn Brands announces new U.S. distribution pact with B&D Nutritional
(NAII) Trading Advice

Media Sentiment Over Time

Entera Bio stock logo

Entera Bio NASDAQ:ENTX

$2.05 +0.01 (+0.49%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.09 +0.04 (+2.15%)
As of 07/18/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

ESSA Pharma stock logo

ESSA Pharma NASDAQ:EPIX

$1.88 +0.01 (+0.53%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.87 -0.01 (-0.53%)
As of 07/18/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

eXoZymes stock logo

eXoZymes NASDAQ:EXOZ

$9.25 0.00 (0.00%)
As of 07/18/2025 10:13 AM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.42 +0.01 (+0.26%)
As of 07/18/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.